The observational study allowed for the pre-screening of potentially eligible patients for the Phase II clinical trial at the sites concerned, enabling such patients to be identified in good time while still in acute stroke care at the hospital. The observational study also monitored eligible stroke patients who did not ultimately participate in the Phase II study on the same end-point measures, thus enabling a broad and valuable clinical data set to be built around the stroke patient sub-population targeted with the CTX stem cell therapy.

Further information regarding our clinical trials, including relevant contact details, may be found on clinicaltrials.gov.